Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721691 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL4736241 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL7677452 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL29991047 | 1.00 | ACHE (0.71) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL6269354 | 0.98 | ACHE (0.68) | ACHEEPHX1EPHX2 | |
| SCHEMBL856878 | 0.93 | ACHE (0.70) | ACHEEPHX2 | |
| SCHEMBL8086223 | 0.92 | ACHE (0.60) | ACHEEPHX1EPHX2 | |
| SCHEMBL13114886 | 0.91 | ACHE (0.62) | ACHEEPHX1EPHX2PAOX | |
| SCHEMBL473096 | 0.91 | ACHE (0.85) | ACHEEPHX1EPHX2 | |
| SCHEMBL10447924 | 0.91 | ACHE (0.85) | ACHEEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6646129-B2 | Treatment of psoriasis and skin cancer | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| EP-0984936-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S | 2002-08-08 | — | — | US | disclosed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | CCNC, MKI67, CCNI | ACHE 3902/4885EPHX1 2486/4885EPHX2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.